CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia

A case report

Chao Ding, MS, Ying Huang, MD, Mingxia Shi, MD, Bo Nie, MS, Yuntao Li, MD, Kun Wu, MS, Jinrong Yang, MS, Yun Zeng, MD

Abstract

Rationale: Second diffuse large B-cell lymphoma (DLBCL) after treatment of acute lymphoblastic leukemia (ALL) is uncommon. To our knowledge, primary middle ear DLBCL which presents CD20-negative and coexpression of MYC and BCL-2 has not been reported yet.

Patient concerns: A 20-year-old Chinese man complained fever and weakness for 2 months. Subsequently bone marrow morphology and flow cytometry immunophenotype suggested ALL. Administered with 9 cycles of multiagent combined chemotherapy, he felt right ear progressive hearing loss, otalgia, aural fullness. Otoneurological examination revealed a pitchy mass obstructing the right external auditory canal. Then the mass resection was performed for biopsy and immunohistochemistry examination.

Diagnosis: The mass was diagnosed as DLBCL which was negative for CD20 and double expression of MYC and BCL-2.

Interventions: Chemotherapy.

Outcomes: The patient eventually gave up and died of severe infection.

Lessons: Although intensive chemotherapy has markedly improved the survival of ALL, more and more secondary cancers have been reported. In addition, primary middle ear lymphoma is much rare; hence, it is easy to be misdiagnosed. Furthermore, DLBCL with negative CD20 and double expression of MYC and BCL-2 is aggressive, which is characterized by chemotherapy resistance and inferior survival rates. We discuss this case aiming at raising awareness of tumors secondary to ALL and exploring the appropriate treatment options for the rare DLBCL.

Abbreviations: ALK = anaplastic lymphoma kinase, ALL = acute lymphoblastic leukemia, AML = acute myeloid leukemia, CMMRD = constitutional mismatch repair deficiency, CNS = central nervous system, CR = complete remission, CT = computed tomography, DEL = double-expression lymphoma, DLBCL = diffuse large B-cell lymphoma, EAC = external auditory canal, EPOCH = etoposide, cyclophosphamide, doxorubicin, vincristine, prednisolone, GCB = germinal center B, HD-MTX = high-dose methotrexate, HHV-8 = human herpesvirus 8, HIV = human immune deficiency virus, IHC = immunohistochemistry, MCD = multicentric Castleman disease, MDS = myelodysplasia, MRD = minimal residual disease, NHL = non-Hodgkin lymphoma, OS = overall survival, PBL = plasmablastic lymphoma, PEL = primary effusion lymphoma.

Keywords: CD20 negative, diffuse large B-cell lymphoma, double expression, poor prognosis, second neoplasms

1. Introduction

Acute lymphoblastic leukemia (ALL) is a malignant tumor originating from lymphoblastic precursor cells. There are 2 onset peaks for ALL, 1 is in childhood (5.3/100,000) and the other is over 80 years old (2.3/100,000). The 5-year overall survival (OS) in children is 90%, while 30% to 40% in adults with conventional cytotoxic chemotherapy. Though pretty good prognosis in children ALL, the secondary neoplasms should not be ignored. According to a multicenter retrospective analysis, the probability of non-Hodgkin lymphoma (NHL) secondary to childhood and adolescent ALL was approximately 0.1%, and 5-year survival rates were 68.5 ± 6.4%. Moreover, CD20-negative NHLs account for a rate of 1% to 2% of all B-cell NHLs with highly aggressive pathologies, high levels of chemotherapy resistance and low survival rates which pose significant diagnostic and treatment challenges.

Herein we report a case of secondary CD20-negative diffuse large B-cell lymphoma (DLBCL) coexpressing MYC and BCL-2,
which originated in middle ear. To the best of our knowledge, this is the 1st case reported in the literature. Due to the rarity, aggressiveness and poor prognosis, the lymphomas need more attention.

2. Case report

A 20-year-old Chinese man complained fever, cough, and weakness for 2 months. In May 2016, he was referred to our hospital. The patient had no family history of malignancy. Blood routine examination indicated severe anemia (hemoglobin 42g/L), visible immature cells (12%). There was 72% blasts in bone marrow aspirate and flow cytometric analysis revealed a population of abnormal cells (86.53%) with immunophenotype of CD19+, cCD79a+, CD34+, HLA-DR+, TDT+, CD10+ (partially), dimCD22+, dimCD33+, CD20/CO, cCD3/CO, CD7/CO, which suggested ALL (common B-ALL). As the chromosome was normal and no BCR/ABL fusion gene was found, he was diagnosed with Philadelphia chromosome-negative ALL. Then he was treated with a cycle of VDCP (vincristine, doxorubicin, cyclophosphamide, prednisolone)-like induction chemotherapy. At the end of 1st cycle, the bone marrow minimal residual disease (MRD) was <0.01%, which indicated molecular complete remission (CR). Then he was administrated 2 courses of HD-MTX (high-dose methotrexate), 1 course HD-MTX plus i-asparaginase, 3 courses of CAM (cyclophosphamide, cytarabine, 6-mercaptopurine), 1 course MA (mitoxantrone, cytarabine) as consolidation chemotherapy, and 6 intensive intrathecal injections of methotrexate, dexamethasone, and cytarabine to prevent central nervous system (CNS) infiltration. During this period, bone marrow morphology or MRD all suggested molecular CR. In December 2017, he felt right ear progressive hearing loss, otalgia, aural fullness. Hospitalization in Department of Otolaryngology in January 2018, oto-endoscopic examination revealed a pitchy mass occluding the right external auditory canal (EAC) and tympanic membrane was not visible. Pure tone audiometry showed a right conductive hearing loss. The temporal bone computed tomography (CT) scan showed a soft-tissue density occupying the right EAC, middle ear, and mastoid antrum (Fig. 1). Then a mass excisional biopsy was performed, the histologic examination indicated a small round cell tumor. The immunohistochemistry (IHC) analysis was positive for MYC (45%), BCL-2 (70%), CD10, CD79a, PAX-5, and negative for MUM-1, BCL-6, CD20 (repeated 3 times), and CD5 (Fig. 2). The immune-proliferative activity (Ki-67 index) was about 80%. The patient was diagnosed with CD20-negative DLBCL coexpressing MYC/BCL-2. According to the Hans classifier,[6] it was classified as germinal center B (GCB) type. Given the lack of CD20 expression, specimens were sent to the West China Hospital, Sichuan University for pathology consultation. They obtained similar IHC staining with a higher Ki-67 index (90%), MYC (70%), and BCL-2 (80%). Moreover, MYC, BCL-2, and BCL-6 translocation was negative in fluorescence in situ hybridization examination. He was hospitalized again in the Department of Hematology 1 month later in February 2018. Bone marrow morphologic was CR for ALL. Laboratory examination showed elevated erythrocyte sedimentation rate 71 mm/h (normal: 0–15 mm/h). The lactate dehydrogenase, β2-microglobulin, human immunodeficiency virus (HIV) showed no abnormality. It was a pity that the patient was not examined by positron emission tomography–CT and we were unable to determine the disease stage accurately. The patient was administrated a course of EPOCH (etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy regimen. He eventually gave up and died of severe infection in June 2018.

3. Discussion

With improved survival rate, it is necessary to evaluate the treatment efficacy on secondary cancers in ALL survivors. Multicenter retrospective studies showed the incidence of second malignant neoplasms among childhood and adult ALL ranges 0.5% to 1.6%. The second cancers includes acute myeloid
leukemia (AML), myelodysplasia (MDS), NHL, and other solid tumors such as brain tumor, thyroid cancer, basal cell carcinoma, lung cancer, etc. Hematologic malignancies develop relatively early, while solid cancers have a longer latency period. Causal factors to be considered are genetic predisposition, the type of previous chemotherapy and/or radiotherapy and their cumulative dose. Alkylating agents and more recently DNA-topoisomerase II inhibitors (i.e., etoposide, mitoxantrone, idarubicin) have been linked to the development of secondary AML and MDS. A major feature of topoisomerase II inhibitors is the generation of DNA double-strand breaks, the repair of which can readily form substrates for inappropriate exchange which may be a risk factor for secondary NHL. Another retrospective study in adults ALL failed to demonstrate a clear relationship between the dose of cyclophosphamide or anthracyclines and the occurrence of secondary neoplasms, because multiagent chemotherapy, as part of multimodality therapy for malignant disease, has increased the difficulty to assess which agents might play a causative role in the development of secondary neoplasms. Until now there is no consistent agreement on whether chemotherapy agent would be a predisposition factor for secondary NHL. Even though several studies have documented a clear relationship between prior irradiation therapy and the occurrence of secondary NHL, sarcomas of bone and thyroid cancer, there was still no evidence of increased risk of secondary NHL even among the most studied group of atomic bomb survivors in Japan. The association of radiotherapy with secondary NHL is difficult to confirm, in contrast to the association with solid tumors.

As we all know, cancer is at its root a genetic disease resulting from the accumulation of mutations that deregulate cellular differentiation, proliferation, and/or survival. The man we report seemed to predispose to hematopoietic malignancies, so there was a question whether he developed a cancer genetic susceptibility syndrome. As a matter of fact, leukemia and lymphomas are seen in association with a number of cancer genetic susceptibility syndromes, and it is estimated that about 2% to 4% of patients with hematopoietic malignancies develop the disease as a result of an underlying predisposition. Cancer genetic susceptibility syndromes are strongly related to family cancer history, presenting features of the tumor and histology, physical examination, or cognitive/developmental manifestation and are associated with risk for hematopoietic cancers. Thereinto, constitutional mismatch repair deficiency (CMMRD) syndrome is related with DNA mismatch repair genes PMS2, MSH6, MSH2, or MLH1. Though poor prognosis, no established and efficient surveillance options are available in CMMRD. We did not consider this rare disease with the patient, as he had no family history of malignancy and had normal cognitive/developmental manifestation.

Extranodal involvement may be present in as many as 30% patients with NHL. The incidence of gastrointestinal tract is the 1st followed by head and neck region. Primary middle ear lymphoma is very rare, which often presents otalgia, moderate to severe conductive hearing loss, low grade fever and facial paralysis. It is a question where the lymphoma origin from, as the normal middle ear cavity does not contain lymphoid tissue. A report suggested that a layer of lymphoid tissue located deep to the epithelium of the mucosa lining the mastoid antrum, tympanic cavity, and tympanic orifice of the eustachian tube acts as the site of origin of the primary lymphoma. CT/magnetic resonance imaging is essential for highly suspected ear lymphoma. Of course, a definitive diagnosis should always be based on pathologic examinations.

The DLBCL is characterized by medium- to large-sized neoplastic cells that express a wide range of B-cell markers including CD19, CD20, CD22, and CD79a. Since CD20-negative DLBCL was reported, several mechanisms for the CD20 phenotypic change after rituximab administration have been proposed, including selection of a CD20-negative clone as a consequence of rituximab exposure or downregulation of the CD20 antigen by genetic and epigenetic changes. As an extremely rare disease, CD20-negative DLBCLs include primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL),
anaplastic lymphoma kinase (ALK)-positive DLBCL, and large B-cell lymphoma arising from human herpesvirus 8 (HHV-8)-associated multicentric Castlemann disease (MCD).[157] They all commonly express markers of plasmacytic differentiation such as CD38, CD138, or MUM-1. The malignancy is commonly related to virus infection such as HIV, HHV-8, and/or Epstein–Barr virus except ALK+ DLBCLs, which are characterized by the chromosomal translocation of the ALK gene to other partner genes (i.e., NPM, CLTC).[28] According to an analysis of the National Cancer Data Base on CD20-negative DLBCL, with a median follow-up time of 2.6 years, median OS was 5 months for PEL, 15 months for PBL, 13 months for ALK+ DLBCL, and it was not reached for HHV-8-DLBCL.[29] Another retrospective study reported the median survival time was <2 months, and the 1-year OS rate was only 24% for HHV-8+DLBCL.[5]

Rituximab, a chimeric CD20 monoclonal antibody, was later developed and approved for treatment of human B-cell malignancies. The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone has dramatically improved the survival of patients with DLBCL.[30] Given the absence of CD20 expression, CD20-negative DLBCLs cannot benefit from rituximab administration and pose a therapeutic dilemma. Until now there is still no standard of care for CD20-negative DLBCL. CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin alternating with ifosfamide, etoposide, cytarabine), dose-adjusted EPOCH and HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with HD-MTX and cytarabine) are the suggested therapies.[4] Novel agents such as proteasome inhibitor bortezomib for PBL,[31] brentuximab for PEL,[32] anti-interleukin-6 monoclonal antibody siltuximab for MCD[33] and crizotinib for ALK+ DLBCL[34] might be promising. Double-expression lymphoma (DEL) exhibits coexpression of BCL-2/MYC on IHC.[35] Approximately 19% to 34% of DLBCL expressed both MYC and BCL-2 protein.[36,37] In various retrospective studies, DEL more frequently had non-GCB type.[16,30,38,39] Compared with patients with DLBCL that did not have overexpression of MYC and BCL2, patients with DEL had worse performance status, more advanced stage, multiple extranodal sites, higher international prognostic index, and higher proliferation index.[40] In addition, patients with DLBCL with coexpression of BCL-2 and MYC but BCL-6 negative expression had a more worse prognosis compared with the patients with coexpression of BCL-2, BCL-6, and MYC.[41] Though no standard treatment for DEL, rituximab plus dose-adjusted EPOCH regimen has shown promising preliminary results.[42] One of new promising targets for patients with DLBCL with BCL-2 and MYC coexpression is heat shock protein H1/105, knockdown of which in a lymphoma mouse model downregulated MYC, BCL-2, and BCL-6 expression, inhibited lymphoma cells proliferation and decreased neoangiogenesis.[43]

To our knowledge, there are no reports on CD20 negative lymphoma with BCL-2 and MYC double expression. As it is poor prognosis for both CD20 negative DLBCL and DLBCL with dual expression of BCL-2 and MYC, CD20-negative DLBCL with BCL-2 and MYC double expression is expected to have a worse prognosis. Dose-adjust EPOCH regimen may be promising for the new type DLBCL.

4. Conclusion
Second NHL as a late side effect of ALL is almost rare. It urges us to pay more attention to the treatment toxicity and to extend the follow-up time. Given no standard regimen and poor prognosis for CD20-negative DLBCL and DEL, we present this case with detailed clinical and pathologic features to increase awareness concerning the rare malignancy among pathologist and clinicians to search more effective treatment strategy to improve the survival rate.

Acknowledgment
Most sincere thanks are given to pathologists and imaging specialist of the First Affiliated Hospital, Kunming Medical University for their kindness of providing all the pathologic and CT images.

Author contributions
Conceptualization: Yun Zeng.
Data curation: Yuntao Li.
Formal analysis: Chao Ding, Mingxia Shi.
Funding acquisition: Yun Zeng.
Investigation: Chao Ding.
Methodology: Yun Zeng.
Project administration: Chao Ding, Mingxia Shi, Bo Nie.
Resources: Ying Huang.
Software: Kun Wu.
Supervision: Jinrong Yang.
Visualization: Mingxia Shi.
Writing – original draft: Chao Ding.
Writing – review & editing: Yun Zeng.

References
[1] Wermann WK, Gokbuget N. Acute lymphoblastic leukemia - diagnostics, subgroups and therapies. Dtsch Med Wochenschr 2018;143: 1311–7.
[2] Kansagara A, Dahiya S, Litzwow M. Continuing challenges and current issues in acute lymphoblastic leukemia. Leuk Lymphoma 2018;59: 526–41.
[3] Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2013;31:2469–76.
[4] Katchi T, Liu D. Diagnosis and treatment of CD20 negative B cell lymphomas. Biomark Res 2017;5:5.
[5] Li J, Zhao S, Wang J, et al. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. Tumour Biol 2016;37:3619–37.
[6] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–82.
[7] Ishida Y, Maeda M, Urayama KY, et al. Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children’s Cancer Study Group protocols: a retrospective cohort study. Br J Haematol 2014;164:101–12.
[8] Kowalczyk J, Armata J, Roksicka-Milewiska R, et al. Incidence and clinical characteristics of second malignant neoplasms in children: a multicenter study of a polish pediatric leukemia/lymphoma group. Med Sci Monit 2004;10:CR117–22.
[9] Tavernier E, Le QH, de Bottom S, et al. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-97 and LALA-94 trials. Cancer 2007;110:2747–55.
[10] Ghimire KB, Shah BK. Second primary malignancies in adult acute lymphoblastic leukemia: a case-control study by the Societe Francaise d’OncoLOGie Pediatric. J Clin Oncol 2003;21:1074–81.
[13] Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1303–6.

[14] Tucker MA, Boice JD Jr, Strong LC, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588–93.

[15] Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003;122:345–59.

[16] Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 1990;121:120–41.

[17] Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333–9.

[18] Zhang J, Walsh MP, Wu G, et al. Germline mutations in predisposition genes: pediatric cancer. N Engl J Med 2015;373:2336–46.

[19] McGee RB, Nichols KE. Introduction to cancer genetic susceptibility syndromes. Hematology Am Soc Hematol Educ Program 2016:2016:293–301.

[20] Ripperger T, Schlegelberger B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet 2016;59:133–42.

[21] Hanna E, Wanamaker J, Adelstein D, et al. Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otolaryngol Head Neck Surg 1997;123:1318–23.

[22] Lang EE, Walsh RM, Leader M. Primary middle-ear lymphoma in a child. J Laryngol Otol 2003;117:205–7.

[23] Vaid S, Jadhav J, Chandorkar A, et al. Bilateral non-Hodgkin lymphoma during childhood and adolescence. Br J Haematol 2003;122:1233–42.

[24] Starr A, Kwon DH, Kallakury B. Epstein-Barr virus-positive CD20- and CD45-negative diffuse large B-cell lymphoma: a diagnostic challenge. Int J Surg Pathol 2018;10:658689618784669.

[25] Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 in CD20-negative diffuse large B-cell lymphoma. Blood 2013;121:2253–63.

[26] Meng Q, Wu J, Hao X, et al. A clinicopathologic analysis of a pediatric patient with CD20-negative diffuse large B-cell lymphoma. J Pediatr Hematol Oncol 2016;2016:2641876.

[27] Li YJ, Li ZM, Rao HL, et al. CD20-negative de novo diffuse large B-cell lymphoma: biology and emerging therapeutic options. Expert Rev Hematol 2015;8:343–54.

[28] Castillo JJ, Chavez JC, Hernandez-Filizalurri FJ, et al. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol 2015;8:343–54.

[29] Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma 2018;59:1375–83.

[30] Kumar A, Fraz MA, Usman M, et al. Treating diffuse large B cell lymphoma in the very old or frail patients. Curr Treat Options Oncol 2018;19:50.

[31] Babas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cetarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010;28:e704–8.

[32] BHATT S, Ashlock BM, Narkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood 2013;122:1233–42.

[33] van Rhee F, Wong RS, Mundhi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:966–74.

[34] Wass M, Behlendorf T, Mottok A, et al. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol 2014;92:268–70.

[35] Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452–9.

[36] Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253–63.

[37] Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273–9.

[38] Hu S, Xu-Monetta ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021–31. quiz 4250.

[39] Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460–7.

[40] Sarkoyu C, Traverse-Glehen A, Costfer B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol 2013;16:e535–67.

[41] Li L, Zhang T, Song Z, et al. Prognostic significance of BCL2- and BCL6 expression in MYC-positive DLBCL. Clin Lymphoma Myeloma Leuk 2018;18:e381–9.

[42] Wilson WH, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:578–65.

[43] Zappasodi R, Ruggiero G, Guarinotta C, et al. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood 2015;125:1766–71.